Last edition
News about "Phase 3 DeLLphi-305 trial,"
Imfinzi-Tarlatamab Combination Improves Overall Survival in Phase 3 ES-SCLC Trial
AstraZeneca and Amgen reported statistically significant improvements in overall and progression-free survival with Imfinzi plus tarlatamab versus Imfinzi alone in the Phase 3 DeLLphi-305 trial.
Phase 3 DeLLphi-305 Trial | 10/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members